Lesson
Airway, Alveolar, and Systemic Biology
COPD emerges from interacting small-airway, alveolar, vascular, immune, and systemic processes. Mucus obstruction, loss of elastic recoil, gas trapping, diffusion impairment, and deconditioning create different clinical patterns.
- Small-airway disease
- Chronic bronchitis
- Emphysema
- Gas trapping and hyperinflation
- Systemic consequences
Inflammation, impaired clearance, fibrosis, and small-airway loss
Emphysema removes attachments and gas-exchange surface
Hyperinflation, inactivity, muscle loss, and multimorbidity interact
Begin in the small airway
Repeated inhaled injury activates epithelial and immune responses, increases mucus, disrupts ciliary clearance, thickens airway walls, and narrows bronchioles. Neutrophils, macrophages, lymphocytes, protease activity, oxidative stress, infection, and altered repair can all contribute. Chronic bronchitis describes cough and sputum clinically, but mucus burden and small-airway disease extend beyond that label.
Define chronic bronchitis without equating it to COPD
The classic definition is cough with sputum for at least three months per year in two consecutive years after excluding other explanations. Chronic bronchitis can occur without spirometric obstruction and does not by itself confirm COPD. Conversely, small-airway mucus plugging can occur despite little productive cough, so absence of the classic syndrome does not exclude mucus-related obstruction.
Follow the loss of elastic recoil
Emphysematous destruction removes alveolar surface area and the attachments that hold small airways open during expiration. Air leaves slowly, gas becomes trapped, and end-expiratory lung volume rises. Dynamic hyperinflation during activity can cause severe breathlessness even when resting oxygenation appears acceptable.
Distinguish resting from dynamic hyperinflation
Loss of recoil can increase end-expiratory lung volume at rest. During exercise, increased breathing demand and shorter expiratory time can worsen incomplete emptying and dynamic hyperinflation. Lung-volume measurements assess hyperinflation; inspiratory capacity at rest and during exercise provides an indirect measure. These mechanical effects are not captured by resting saturation or FEV1 alone.
Connect ventilation to gas exchange
Ventilation-perfusion mismatch is a major cause of abnormal gas exchange in COPD. Emphysema can also reduce diffusion capacity, and impaired ventilation can produce hypercapnia. Pulse oximetry cannot reveal carbon dioxide or acid-base status, so blood gas testing is required when ventilatory failure is possible.
Connect vascular change to right-heart burden
Loss of pulmonary capillary bed and hypoxic vasoconstriction can contribute to pulmonary hypertension. Progressive pressure elevation may strain the right ventricle and lead to right-sided heart failure, or cor pulmonale. Severe pulmonary hypertension is uncommon in COPD; it is not an inevitable consequence in every patient.
Treat the disease outside the lung
Inactivity, skeletal muscle dysfunction, weight loss, frailty, osteoporosis, cardiovascular disease, anxiety, depression, and social barriers amplify respiratory disability. Pulmonary rehabilitation, nutrition, comorbidity care, exposure reduction, and medication therapy operate on connected parts of the same illness.
Quick check
Checking for saved practice…
Lesson
Definition, Diagnosis, and Etiotypes
COPD is a heterogeneous condition with chronic respiratory symptoms caused by airway and or alveolar abnormalities that produce persistent, often progressive airflow obstruction.
- Clinical context
- Post-bronchodilator spirometry
- Airway and alveolar pathology
- Life-course etiotypes
- Pre-COPD and PRISm
Dyspnea, cough, sputum, infection, and lifetime lung injury
FEV1/FVC below 0.70; check quality and repeat borderline results
Airway, emphysema, development, genetics, and environment
Understand the measured volumes
FEV1 is forced expiratory volume in the first second of a forced exhalation. FVC is forced vital capacity, the total volume exhaled during the forced maneuver after a full inspiration. Dividing these measured volumes gives FEV1/FVC, a dimensionless ratio used to identify obstruction. FEV1 percent predicted instead compares the measured FEV1 with a reference value; it describes airflow impairment after obstruction is established and is not the same calculation.
Require context and spirometry
Consider COPD with persistent dyspnea, activity limitation, cough, sputum, recurrent lower respiratory infection, or exacerbations plus tobacco, biomass, occupational, pollution, developmental, genetic, or other risk. Confirm with post-bronchodilator FEV1 divided by FVC below 0.70. Pre-bronchodilator testing can help exclude obstruction, but it does not replace post-bronchodilator confirmation.
Interpret the ratio carefully
A fixed ratio improves consistency but can overdiagnose some older adults and underdiagnose some younger adults. Repeat a post-bronchodilator ratio near the threshold, verify effort and quality, compare the clinical pattern, and consider lower-limit-of-normal interpretation when discordance matters. Reversibility magnitude does not reliably separate COPD from asthma.
Repeat results in the diagnostic uncertainty range
GOLD recommends repeating spirometry on a separate occasion when a single post-bronchodilator FEV1/FVC lies between 0.60 and 0.80. For example, FEV1 1.8 L divided by FVC 2.7 L is about 0.67: obstruction is present on that test, but repeat confirmation and compatible clinical context remain necessary. This ratio is not FEV1 percent predicted.
Avoid an absolute asthma-versus-COPD checklist
Persistent obstruction can occur in asthma as well as COPD. The magnitude of bronchodilator response does not reliably distinguish them or predict long-term medication response. Age and exposure patterns inform the differential but are not substitutes for the full clinical history. A nonobstructed pre-bronchodilator result usually avoids further bronchodilator testing, but very high clinical suspicion warrants further evaluation: an increase in FVC after bronchodilation can occasionally reveal obstruction.
Connect structure to physiology
Small-airway inflammation, mucus, fibrosis, loss of alveolar attachments, emphysematous destruction, gas trapping, hyperinflation, vascular change, and impaired gas exchange contribute differently across patients. FEV1 captures obstruction but not the full burden of hyperinflation, diffusion loss, exercise limitation, or symptoms.
Separate lung development from later decline
COPD may arise from low peak lung function after impaired development, accelerated decline later in life, or both. Prematurity and childhood respiratory illness can matter alongside adult exposures. Mild airflow obstruction describes present spirometric impairment, not necessarily early biological disease. Young adults can have substantial structural or functional disease.
Explain the inherited protection deficit
Alpha-1 antitrypsin is a proteinase inhibitor that helps restrain neutrophil elastase. Deficiency leaves lung connective tissue more vulnerable to proteolytic injury and emphysema. Tobacco and occupational exposures can worsen risk, but smoking is not required for inherited deficiency to matter. Identifying the cause supports exposure counseling, family testing, and specialist assessment rather than assuming that all COPD has the same origin.
Test for alpha-1 antitrypsin deficiency
GOLD recommends AAT-deficiency testing in all patients diagnosed with COPD. Older age, cigarette exposure, or an upper-lung emphysema pattern does not exclude it. A serum concentration alone cannot fully characterize inherited risk: inflammation can alter levels and genotypes can overlap. The AATD guideline recommends at least S and Z genotyping for symptomatic diagnostic testing, with confirmation using an independent method such as phenotype, level, or expanded genetic testing as appropriate. Arrange specialist assessment and offer family counseling and testing when a pathogenic variant is identified.
Use a life-course model
Tobacco remains important, but COPD can arise from biomass and occupational exposure, air pollution, alpha-1 antitrypsin deficiency, infection, impaired lung development, prematurity, tuberculosis, asthma, and accelerated aging. Pre-COPD describes symptoms or structural or functional abnormality without obstruction. PRISm means post-bronchodilator FEV1 below 80% predicted with FEV1/FVC at least 0.70. These patients need evaluation and follow-up; progression to COPD is not inevitable. PRISm can persist or transition to normal or obstructed spirometry. The optimal medication treatment for pre-COPD or PRISm is not established; investigate the abnormalities and reduce risk rather than automatically prescribing a standard COPD regimen. Neither should be mislabeled established COPD without post-bronchodilator obstruction.
Quick check
Checking for saved practice…
Lesson
Severity, Symptoms, Exacerbations, and Multimorbidity
Airflow grade, symptom burden, exacerbation risk, disease activity, gas exchange, imaging, function, and comorbidity describe different dimensions of COPD.
- GOLD airflow grade
- mMRC and CAAT
- ABE assessment
- Disease activity
- Multimorbidity
Obstruction, hyperinflation, diffusion, gas exchange, and exercise
Breathlessness, activity, cough, sleep, energy, and daily impact
Initial Group E: at least one moderate or severe event in the prior year
Keep spirometry and lived burden separate
Grade airflow obstruction from post-bronchodilator FEV1 percent predicted, then measure symptoms with mMRC and the COPD Assessment Test, now called CAAT in GOLD materials. Severe obstruction can coexist with modest reported symptoms, while major dyspnea can reflect hyperinflation, deconditioning, cardiac disease, anemia, obesity, anxiety, or another process.
Check the reference behind percent predicted
FEV1 percent predicted is the measured FEV1 divided by the predicted reference FEV1, multiplied by 100. GOLD 2026 recommends the race-neutral GLI-Global reference equations for assessing lung function impairment, while acknowledging their limitations. Verify the laboratory reference and test quality when interpreting a result. GOLD retains percent-predicted airflow grades for COPD; an ATS/ERS z-score severity category is a different framework and should not be silently substituted for a GOLD grade.
Assign airflow grade with explicit boundaries
After confirming obstruction, use post-bronchodilator FEV1 percent predicted: GOLD 1 is at least 80%; GOLD 2 is 50% to below 80%; GOLD 3 is 30% to below 50%; GOLD 4 is below 30%. These grades describe airflow obstruction, not the ABE treatment group. Thus 50% belongs to grade 2 and 30% to grade 3.
Quantify symptoms before assigning A or B
The ABE symptom thresholds are mMRC 0 to 1 versus at least 2, or CAAT below 10 versus at least 10. Apply these alongside the prior-year exacerbation history. For example, a patient with post-bronchodilator FEV1/FVC 0.62, FEV1 55% predicted, CAAT 14 and no moderate or severe exacerbations is grade 2, Group B. One steroid-treated exacerbation instead places that patient in Group E under GOLD 2026; the spirometric grade stays 2.
Understand what symptom scores measure
mMRC measures breathlessness on a 0 to 4 scale. CAAT means Chronic Airways Assessment Test, the renamed CAT; their scores are interchangeable. CAAT has eight items and a total from 0 to 40. A low mMRC can coexist with substantial cough, sleep, energy, or other burden. Prefer a comprehensive assessment and do not invent a numerical conversion or average between these different scales.
Use eosinophils for the right question
Blood eosinophils help estimate the preventive benefit of adding ICS to maintenance bronchodilation. Interpret them with exacerbation history and the existing regimen. Evidence is insufficient to use a count alone to predict an individual patient's future exacerbations; it does not replace symptom, spirometric, or comorbidity assessment.
Apply the 2026 ABE threshold
Treatment-naive Group A has lower symptoms and no moderate or severe exacerbation in the prior year. Group B has greater symptoms and no moderate or severe exacerbation. Group E includes at least one moderate or severe exacerbation in the prior year, regardless of symptom score. This 2026 threshold reflects the risk carried by even one treated event.
Describe activity and trajectory
Track symptoms, rescue use, lung function, moderate and severe exacerbations, admissions, activity, weight, oxygenation, and treatment response over time. A quiet interval after a recent attack does not erase active risk. Past-event records often use treatment and healthcare use: systemic steroid or antibiotic treatment identifies a moderate event, and emergency or inpatient care a severe event. These retrospective labels are not a complete point-of-care severity assessment. GOLD 2026 favors the Rome approach using current dyspnea, respiratory and heart rates, oxygenation, and available laboratory findings; hospitalization alone does not define the acute physiology.
Actively seek multimorbidity
Evaluate cardiovascular disease, lung cancer eligibility, bronchiectasis, anxiety and depression, osteoporosis, sarcopenia, malnutrition, obesity, sleep apnea, reflux, diabetes, anemia, frailty, and medication burden. Treat these conditions by their usual standards. Cardioselective beta blockers should not be withheld when a cardiovascular indication exists. They should not be initiated solely to prevent COPD exacerbations without an appropriate cardiovascular indication.
Quick check
Checking for saved practice…
Lesson
Bronchodilators, Anti-Inflammatory Drugs, and Devices
Long-acting bronchodilation is the treatment core. Anti-inflammatory benefit depends on phenotype, exacerbation history, molecule, route, and toxicity.
- Beta2 agonists
- Muscarinic antagonists
- ICS benefit and harm
- PDE inhibition
- Device matching
LABA relaxes airway smooth muscle through adrenergic signaling
LAMA reduces cholinergic bronchoconstrictor tone
Selected anti-inflammatory therapy; ensifentrine also bronchodilates
Calculate nebulized ipratropium concentration
Single-ingredient ipratropium 0.02% contains 0.02 g per 100 mL, or 0.2 mg/mL. A 2.5 mL vial therefore supplies 0.5 mg (500 mcg). The labeled maintenance regimen is one vial three to four times daily, six to eight hours apart. This is a nebulized dose, not a puff-for-puff conversion from Atrovent HFA.
Check nebulizer compatibility at the product level
The reviewed single-ingredient ipratropium label permits mixing with albuterol or metaproterenol if used within one hour; it does not establish compatibility with other medicines. Do not extend that permission to every nebulized product. Protect the eyes from mist; a mouthpiece can reduce eye exposure, and a mask must fit without leakage. Clean the apparatus according to its manufacturer.
Read both strengths on the combination vial
The ready-to-use 3 mL ipratropium-albuterol vial contains ipratropium 0.5 mg and albuterol sulfate 3 mg, equivalent to albuterol base 2.5 mg. These albuterol numbers describe the same amount of active drug, not two different doses. Nebulize one vial four times daily; labeling permits up to two additional vials daily if needed under the prescribed plan. Failure of usual relief requires prompt reassessment rather than continued dose escalation.
Use the combination solution without dilution
Administer the whole single-dose vial through a compressor-driven jet nebulizer with a mouthpiece or suitable mask; no dilution is needed. Keep mist out of the eyes, use a fresh vial for each treatment, and follow device cleaning instructions. The reviewed label specifies storage at 20 to 25 degrees Celsius with light protection in its pouch or carton. Follow the dispensed product instructions rather than borrowing another manufacturer’s opened-pouch deadline.
Match inspiratory effort to the device
pMDIs and soft-mist inhalers generally require slow, deep inspiration, while DPIs require forceful inspiration through their specific internal resistance. Observe use and assess inspiratory flow when ability is uncertain. Consider a suitable alternative system, including a pMDI with an appropriate spacer when needed, rather than assuming that extra prescribed doses overcome poor delivery. Product instructions remain decisive.
Verify delivery after every device change
A nebulizer is not generally superior to a handheld inhaler that the patient can use properly. Match treatment to capability, medicine availability, preferences, and practical needs. Demonstrate technique, ask the patient to show it back, and repeat checks over time. A device switch requires retraining; a leaflet or refill record alone does not establish effective use.
Dose Atrovent HFA by its delivered strength
Atrovent HFA delivers 17 mcg ipratropium per puff. The usual regimen is two puffs four times daily, with a maximum of 12 puffs in 24 hours. It is labeled for COPD maintenance, not initial rapid rescue of acute bronchospasm. Ipratropium, component, or atropine-derivative hypersensitivity contraindicates use. Avoid additive anticholinergic medicines and review urinary retention and narrow-angle glaucoma risk.
Prepare and clean Atrovent HFA correctly
Shaking is unnecessary. Prime with two sprays away from the face initially and after more than three unused days. Inhale slowly and deeply while actuating; hold the breath for ten seconds and wait at least 15 seconds before the second puff. Keep spray out of the eyes. Weekly, remove the canister and cap, rinse the mouthpiece with warm running water for at least 30 seconds, and let it dry completely before reassembly. Discard at a zero dose indicator even if the canister still contains liquid.
Distinguish Combivent Respimat from other Respimat doses
Each Combivent puff delivers ipratropium 20 mcg plus albuterol 100 mcg. Its COPD regimen is one puff four times daily, maximum six in 24 hours. Do not transfer the two-puff dose used by some other Respimat products. Review the entire bronchodilator list before adding doses: extra ipratropium or albuterol beyond the recommended combination regimen has not been established as safe and effective.
Prime and maintain Combivent Respimat
Insert the matching cartridge before priming. Release sprays toward the ground until mist appears, then repeat three more times. After more than three unused days release one spray; after more than 21 days repeat full priming. Use the turn-open-press sequence. Clean the mouthpiece, including its inner metal part, weekly with a damp cloth or tissue. Store at 20 to 25 degrees Celsius without freezing. Discard three months after cartridge insertion, at lockout, or at expiration, whichever occurs first.
Relax airway smooth muscle through two pathways
Beta2 agonists increase cyclic AMP, while muscarinic antagonists block acetylcholine-driven M3 bronchoconstriction. LABA and LAMA combinations improve bronchodilation through complementary mechanisms. Short-acting bronchodilators remain rescue options, but regular long-acting treatment better supports persistent symptoms.
Recognize systemic beta-agonist effects
Beta2 agonists can cause tremor, nervousness, palpitations and tachycardia. Excess exposure increases cardiovascular risk, including arrhythmias; review total LABA and rescue use when these symptoms develop. Potassium may shift into cells and blood glucose may rise, although clinically important changes are uncommon with recommended salmeterol doses. Non-potassium-sparing diuretics can worsen hypokalemia or ECG effects. Review cardiovascular disease and interacting medicines; do not assume an inhaled route eliminates systemic effects.
Distinguish arformoterol from formoterol
The reviewed Brovana brand record lists a December 31, 2025 marketing end date. Its retained label explains the historical product and does not establish current stock or the availability of every generic arformoterol product. Verify the dispensed manufacturer and its instructions. Brovana contains arformoterol: nebulize one 15 mcg/2 mL vial every 12 hours through a compressor-driven jet nebulizer, for a maximum of 30 mcg daily. It maintains COPD bronchodilation; it does not treat asthma or an acute attack. Do not combine it with another LABA. Mixing with other nebulized medicines has not been established as safe or effective. Hypersensitivity to arformoterol, racemic formoterol, or another ingredient is a contraindication.
Use the Brovana storage clock
Keep vials refrigerated at 2 to 8 degrees Celsius in protective foil. Unopened foil pouches may instead remain at 20 to 25 degrees Celsius for up to six weeks (42 days), or until expiration if sooner. Record the room-temperature deadline. Use an opened vial immediately and discard discolored solution. Do not transfer the Perforomist room-temperature storage interval to Brovana.
Count both Striverdi puffs as one daily dose
Striverdi Respimat contains olodaterol, a LABA for COPD maintenance, not asthma or rescue treatment. Each puff delivers 2.5 mcg; two puffs once daily deliver 5 mcg. Do not exceed two puffs in 24 hours or add another LABA. After turning the base and opening the cap, exhale away, seal lips without blocking vents, and press while inhaling slowly and deeply. Hold the breath up to ten seconds as comfortable, then repeat for the second puff.
Prime and retire Striverdi correctly
After cartridge insertion, spray toward the ground until mist appears, then repeat three more times. After more than three unused days, release one preparation puff; after more than 21 days, repeat the full mist-plus-three sequence. Store at 20 to 25 degrees Celsius without freezing. Discard at three months after cartridge insertion, device lock, or expiration, whichever occurs first. Wipe the mouthpiece and its inner metal part with a damp cloth or tissue at least weekly.
Keep nebulized formoterol separate from asthma MART
Perforomist is single-ingredient formoterol for adult COPD maintenance: one 20 mcg/2 mL vial every 12 hours through a compressor-driven jet nebulizer. It is not labeled for asthma or acute relief. Its formoterol ingredient does not make it interchangeable with an ICS-formoterol inhaler. Avoid another LABA and retain the prescribed short-acting rescue medicine.
Preserve Perforomist preparation and storage
Keep each vial in its light-protective foil until immediately before treatment; discard any remainder after opening. Do not mix it with other nebulized medicines because compatibility and clinical performance are unestablished. Refrigerate at 2 to 8 degrees C before dispensing. After dispensing, the label permits refrigeration until expiry or 20 to 25 degrees C storage for up to three months; record the applicable deadline and never extend expiry.
Take two breaths from one HandiHaler capsule
Spiriva HandiHaler is tiotropium for COPD maintenance and exacerbation reduction, not rescue. Once daily, inhale twice from the same 18 mcg capsule using HandiHaler; do not use two capsules or swallow the capsule. Remove it from its blister immediately before use, place it in the center chamber, close the mouthpiece, and press and release the piercing button once. Exhale away, inhale deeply with vents unobstructed, hold briefly, and repeat the inhalation without piercing again. Discard the used capsule.
Protect the HandiHaler and review its cautions
Keep capsules sealed and dry. Clean HandiHaler as needed with warm water, without detergent, and allow 24 hours to air-dry completely before reuse. Tiotropium, ipratropium, or product-ingredient hypersensitivity contraindicates treatment. Severe milk-protein hypersensitivity is a labeled caution for HandiHaler. With creatinine clearance below 60 mL/min, monitor closely for anticholinergic adverse effects rather than assuming renal impairment is irrelevant to an inhaled drug.
Keep Spiriva device and indication doses distinct
For COPD, Spiriva Respimat uses two 2.5 mcg inhalations once daily, totaling 5 mcg. Its US asthma regimen from age six uses two 1.25 mcg inhalations, totaling 2.5 mcg daily. HandiHaler has a COPD indication; do not transfer the Respimat asthma indication to its capsules. Neither formulation is rescue therapy. Respimat cartridges are specific to their labeled inhaler and cannot be exchanged among different Respimat products.
Recognize the discontinued Lonhala Magnair system
The book includes Lonhala Magnair, but Drugs@FDA now lists its marketing status as discontinued. Its historical glycopyrrolate regimen was one 25 mcg/1 mL vial twice daily for COPD maintenance, using only the Magnair device. It was not a generic instruction to nebulize glycopyrrolate through any system. The label required room-temperature storage in protective foil and disposal of unused vials seven days after pouch opening. Preserve this distinction when interpreting older records; choose available treatment with the prescriber rather than substituting devices or formulations.
Select a nebulized LAMA deliberately
Yupelri contains revefenacin: inhale one 175 mcg/3 mL vial once daily through a compressor-driven jet nebulizer with a mouthpiece for COPD maintenance, not rescue. The label establishes performance with the PARI LC Sprint and Trek S system, not non-compressor systems. Open the foil and vial immediately before use; discard leftover solution. Compatibility, safety, and efficacy of mixing with other nebulized drugs are unestablished. The label does not recommend use with any degree of hepatic impairment or with OATP1B1/1B3 inhibitors such as cyclosporine or rifampicin. Review these transporter interactions rather than assuming only enzyme induction matters.
Use one Incruse dose each day
Incruse Ellipta supplies umeclidinium 62.5 mcg per actuation. Take one inhalation daily at the same time for COPD maintenance, never extra doses for acute symptoms. Severe milk-protein allergy or hypersensitivity to its ingredients contraindicates use. Opening the cover prepares a dose; opening and closing without inhaling wastes that dose. Record tray opening and discard at six weeks or a zero counter, whichever occurs first. Store dry at 20 to 25 degrees Celsius, away from heat and sunlight.
Complete the Ellipta inhalation sequence
For Incruse Ellipta, slide the cover until it clicks and confirm the counter decreases. Exhale fully away from the device, seal the mouthpiece with your lips, and take a sustained, deep, steady breath through your mouth with the air vent unobstructed. Remove the device, hold your breath for about three to four seconds or as comfortable, then exhale gently and close the cover. Lack of taste or sensation does not justify another dose. If needed, wipe the mouthpiece with a dry tissue; no routine washing is required. Follow the exact product instructions, including rinsing and spitting after ICS-containing treatment.
Match aclidinium to the Pressair schedule
Tudorza Pressair delivers a labeled 400 mcg aclidinium bromide dose by one inhalation approximately every 12 hours. It is COPD maintenance, not rescue. Severe milk-protein allergy or ingredient hypersensitivity contraindicates use. Discard at 45 days after bag opening, zero on the dose indicator, or empty-device lockout, whichever comes first. Keep dry; clean the mouthpiece with a dry tissue, never water.
Confirm Tudorza delivery with the control window
Press and fully release the green button; the window should turn green before inhalation. Exhale away, seal the mouthpiece, and inhale strongly and deeply, continuing beyond the click. Do not hold the button down. Hold the breath as tolerated, then exhale away. A red window confirms delivery. If it stays green, repeat the inhalation steps without loading another dose; seek device help if repeated attempts fail. Absence of a taste alone is not a reason for another dose.
Recognize antimuscarinic warning symptoms
For revefenacin, umeclidinium, and aclidinium, review narrow-angle glaucoma, urinary retention, and other anticholinergic medicines before treatment. Avoid additive anticholinergic exposure. Eye pain with halos or blurred vision, or painful or difficult urination, needs prompt medical assessment. Stop the implicated inhaler and obtain treatment for paradoxical bronchospasm or an immediate hypersensitivity reaction; do not keep repeating maintenance doses to treat worsening breathing.
Identify both ingredients in Anoro
Anoro Ellipta combines umeclidinium 62.5 mcg with vilanterol 25 mcg in one inhalation once daily. This LAMA-LABA provides COPD maintenance without an inhaled corticosteroid; it is not labeled for asthma or acute relief. Avoid another LABA and additional anticholinergic therapy. Severe milk-protein or ingredient hypersensitivity contraindicates use. Strong CYP3A4 inhibitors require caution because vilanterol exposure and cardiovascular effects may increase. Discard six weeks after opening the foil tray or when the counter reaches zero, whichever comes first.
Count Stiolto doses by both ingredients
Stiolto Respimat combines tiotropium and olodaterol. Each puff supplies 2.5 mcg of each; two puffs once daily deliver 5 mcg of each ingredient. It is COPD maintenance, not asthma treatment or rescue. Do not add another LABA or anticholinergic-containing medicine. This combination already supplies the ingredients in Spiriva and Striverdi. Hypersensitivity to tiotropium, ipratropium, olodaterol, or another ingredient contraindicates use. Monitor anticholinergic effects closely with moderate or severe renal impairment.
Prepare Stiolto before its treatment puffs
Prime a newly assembled Stiolto by spraying toward the ground until mist appears, then repeating three times. After more than three unused days, release one preparation puff; after more than 21 days, repeat the full sequence. These preparation sprays are separate from the two daily inhalations. The IFU starts the three-month discard clock at cartridge insertion; replace sooner if empty and locked. Keep at 20 to 25 degrees Celsius without freezing, and wipe the mouthpiece weekly with a damp cloth or tissue.
Calculate the Bevespi dose per treatment
Bevespi Aerosphere contains glycopyrrolate 9 mcg and formoterol fumarate 4.8 mcg per puff. Two puffs morning and evening provide 18/9.6 mcg per treatment. This LAMA-LABA is COPD maintenance, not asthma or rescue therapy. Do not add another LABA or anticholinergic-containing medicine. Severe renal impairment requires weighing expected benefit against risk.
Prime and clean Bevespi as an aerosol
Shake before each puff. Initially prime with four sprays away from the face; after more than seven unused days or after cleaning, re-prime with two. Coordinate actuation with slow, deep inhalation. Weekly, remove the canister, keep it dry, rinse the plastic actuator with warm water, and air-dry overnight before reassembly. Discard at a zero counter or three months after foil-pouch opening, whichever comes first.
Prescribe Duaklir as one inhalation twice daily
Duaklir Pressair is aclidinium bromide/formoterol fumarate 400/12 mcg: one inhalation morning and evening, not two inhalations per treatment. It is a dry-powder COPD maintenance LAMA-LABA, not rescue or asthma treatment. Severe milk-protein or ingredient hypersensitivity contraindicates use. Do not add another LABA. The formoterol ingredient does not make this an ICS-formoterol asthma reliever.
Check Duaklir delivery and its own discard date
Press and release the orange button to load the dose; confirm the window is green. Exhale away, seal the mouthpiece, and inhale strongly and deeply without holding the button, continuing beyond the click. The window should return to red; if it remains green, repeat the inhalation steps without loading another dose. Keep the device dry. Discard two months after bag opening, at zero on the indicator, or empty-device lockout, whichever comes first. Do not copy Tudorza's 45-day deadline merely because both use Pressair devices.
Use ICS for exacerbation biology, not isolated dyspnea
ICS benefit rises with exacerbation history and higher blood eosinophils. Triple LABA-LAMA-ICS therapy is preferred over LABA-ICS when an ICS is indicated. Consider pneumonia, oral candidiasis, dysphonia, skin bruising, bone, metabolic, eye, mycobacterial, and systemic exposure risks. Asthma features create a separate need to follow asthma ICS principles.
Match budesonide-formoterol to its formulation
For COPD, conventional Symbicort uses two 160/4.5 mcg inhalations twice daily, totaling 320/9 mcg per administration. Symbicort Aerosphere uses two 160/4.8 mcg inhalations twice daily, totaling 320/9.6 mcg per administration. Confirm the exact product and device rather than treating these strengths as interchangeable instructions. Both are maintenance-label regimens; do not import an asthma MART schedule into COPD or add another LABA. Rinse and spit after ICS-containing treatment.
Use the COPD strength of fluticasone-salmeterol
Advair Diskus and Wixela Inhub contain fluticasone propionate and salmeterol. Their approved COPD regimen is one 250/50 mcg inhalation twice daily, about 12 hours apart. The 500/50 asthma strength has not demonstrated an efficacy advantage over 250/50 for COPD and is not their approved COPD dose. The ingredients match, but Diskus and Inhub loading instructions differ; demonstrate the dispensed device. Rinse and spit after use, retain a short-acting rescue medicine, and avoid another LABA.
Separate Breo COPD dosing from asthma dosing
Breo Ellipta contains fluticasone furoate and vilanterol. COPD uses one 100/25 mcg inhalation once daily; the 200/25 strength is an adult asthma option, not the labeled COPD regimen. It is not an acute reliever. A patient with breathlessness between doses needs the prescribed rescue medicine and reassessment when symptoms are worsening, not extra Breo inhalations. Match the need for ICS to the treatment strategy rather than selecting a higher steroid strength simply because it exists.
Use the COPD strength of Trelegy
Trelegy Ellipta combines fluticasone furoate, umeclidinium and vilanterol: ICS, LAMA and LABA. The COPD regimen is one 100/62.5/25 mcg inhalation once daily. The 200/62.5/25 strength is an asthma option, not the approved COPD strength. Count all three ingredients during reconciliation so a switch does not unintentionally retain another LABA or LAMA. This is maintenance treatment; acute breathlessness requires the prescribed rescue medicine.
Separate Breztri COPD and asthma strengths
Breztri Aerosphere combines budesonide, glycopyrrolate and formoterol fumarate. Adult COPD uses two 160/9/4.8 mcg puffs twice daily, totaling 320/18/9.6 mcg per administration. Its April 2026 US label also includes asthma from age 12, using two 160/18/4.8 mcg puffs twice daily. The glycopyrrolate strength differs; verify indication and canister rather than transferring one regimen to the other. Neither regimen is rescue. Rinse and spit after treatment, avoid duplicate LABA or anticholinergics, and monitor for pneumonia and candidiasis.
Keep salmeterol maintenance separate from rescue
Serevent Diskus supplies salmeterol 50 mcg per inhalation; COPD maintenance uses one inhalation twice daily. It does not treat acute bronchospasm and should not be combined with another LABA. Severe milk-protein or ingredient hypersensitivity contraindicates use. Its asthma-related-death warning addresses LABA treatment without ICS in asthma; the COPD indication does not authorize LABA-only treatment when the patient also has asthma.
Know the phosphodiesterase options
Roflumilast is an oral selective PDE4 inhibitor used to reduce exacerbation risk in selected patients with severe obstruction, chronic bronchitis, and recurrent attacks, especially after hospitalization. It is not a bronchodilator. Monitor diarrhea, weight loss, sleep, mood, and suicidality. Ensifentrine inhibits PDE3 and PDE4 and is FDA-labeled as twice-daily nebulized adult maintenance therapy. It is not rescue treatment and requires psychiatric, hepatic, paradoxical-bronchospasm, and device counseling.
Prepare ensifentrine as a suspension
Ohtuvayre supplies 3 mg in 2.5 mL per ampule. Nebulize one entire ampule morning and evening using a standard jet nebulizer, mouthpiece, and compressor. Shake vigorously immediately before use. Do not swallow, inject, or mix it with other medicines. Extra doses do not treat acute bronchospasm.
Track the opened ensifentrine pouch
Keep ampules upright in their protective pouch and carton at 20 to 25 degrees Celsius, away from excessive heat and direct sunlight; do not freeze. Open an ampule only for immediate use. For five-ampule pouches, return unused ampules to the pouch and discard any remaining after 14 days from opening. Discard the used ampule and residual contents; follow device cleaning instructions.
Distinguish ensifentrine precautions from roflumilast
Hepatic impairment requires caution because ensifentrine exposure increases; do not transfer roflumilast’s hepatic contraindication to this product. Mild or moderate renal impairment needs no dose adjustment; severe impairment has not been evaluated. Ingredient hypersensitivity contraindicates use. Review psychiatric symptoms, including suicidality. Paradoxical bronchospasm requires immediate discontinuation, short-acting bronchodilator treatment, and alternative therapy.
Treat the device as part of the prescription
Metered-dose, dry-powder, soft-mist, and nebulized systems differ in inspiratory flow, coordination, dexterity, preparation, cleaning, portability, and cost. Observe inhalation, check the dose counter and supply, and simplify when possible. A nebulizer can help selected patients but is not inherently more effective when a handheld device is used correctly.
Quick check
Checking for saved practice…
Lesson
Advanced Anti-Inflammatory and Phenotype Therapy
Persistent exacerbations after optimized bronchodilation require a phenotype and implementation review. ICS, roflumilast, macrolide prevention, and biologic therapy address different risk patterns and carry different harms.
- ICS response probability
- Roflumilast
- Azithromycin prevention
- Dupilumab
- Mepolizumab
Use events, eosinophils, eligibility, and drug-specific safety risks
Target recurrent attacks with severe obstruction and chronic bronchitis
Audit rhythm, hearing, microbiology, resistance, and duration
Estimate corticosteroid benefit
Prior exacerbations and blood eosinophils estimate the probability of ICS benefit. Benefit is generally greater at higher eosinophil counts and low below 100 cells per microliter. Review pneumonia, mycobacterial disease, oral candidiasis, dysphonia, bruising, bone, eye, metabolic, dose, and smoking risks. When ICS is indicated, triple LABA-LAMA-ICS is preferred over routine LABA-ICS.
Match roflumilast to chronic bronchitis
Roflumilast is an oral PDE4 anti-inflammatory medicine for selected patients with severe airflow obstruction, chronic bronchitis, and recurrent exacerbations, especially after hospitalization. PDE4 inhibition reduces breakdown of intracellular cyclic AMP and has anti-inflammatory effects; roflumilast is not a direct bronchodilator. GOLD advises avoiding it in underweight patients. Review hepatic function, weight, diarrhea, nausea, sleep, mood, suicidality, and interacting enzyme inducers before and during treatment.
Separate roflumilast initiation from maintenance
The effective oral dose is 500 mcg daily, with or without food. An optional 250 mcg daily lead-in for four weeks may improve tolerability before increasing to 500 mcg. Continuing 250 mcg indefinitely is not an effective maintenance strategy. This medicine prevents exacerbations; it does not relieve acute bronchospasm.
Screen liver function, weight, and mood
Child-Pugh B or C hepatic impairment is a contraindication; Child-Pugh A requires individualized benefit-risk assessment. Renal impairment does not require dose adjustment. Monitor weight, appetite, gastrointestinal tolerance, sleep, and mood. Evaluate unexplained or significant weight loss and consider stopping. New depression, anxiety, insomnia, or suicidal thoughts require prompt clinical assessment, including reassessment of continued treatment.
Check both directions of enzyme interactions
Rifampin, carbamazepine, phenytoin, and phenobarbital can reduce roflumilast exposure and effectiveness; concurrent use is not recommended. CYP3A4 inhibitors or combined CYP3A4/CYP1A2 inhibitors, including erythromycin, ketoconazole, fluvoxamine, and cimetidine, can increase exposure and adverse effects. Assess benefit versus risk before combining them.
Use chronic macrolide therapy deliberately
Azithromycin may reduce exacerbations in selected patients, particularly former smokers, after optimized inhaled treatment. Before long-term use, review QT interval, rhythm and interacting drugs, hearing, liver function, sputum microbiology when indicated, nontuberculous mycobacteria, resistance pressure, bronchiectasis, and a planned duration and response audit.
Define a monitored macrolide trial
GOLD describes azithromycin 250 mg daily or 500 mg three times weekly for one year in exacerbation-prone patients. Benefit may be smaller in active smokers; resistance, QT prolongation, and hearing impairment remain concerns. Evidence does not establish preventive efficacy or safety beyond one year. Record baseline exacerbations and reassess measurable benefit rather than renewing indefinitely.
Use specialist safety screening and follow-up
The BTS long-term macrolide guideline recommends respiratory-specialist discussion, baseline ECG and liver tests, and sputum assessment including nontuberculous mycobacteria (NTM). Its initiation QTc contraindication thresholds are greater than 450 ms for men or 470 ms for women. Avoid macrolide monotherapy when NTM is identified; consider CT for possible bronchiectasis. Recheck ECG and liver tests after one month, then liver tests every six months. Stop for new QT prolongation; reassess benefit at six and twelve months and stop if ineffective. Include hearing, balance, gastrointestinal symptoms, and interactions in follow-up.
Apply current biologic labels
Dupilumab blocks IL-4 receptor alpha signaling and mepolizumab targets IL-5. Current US labeling supports add-on maintenance use in selected adults with inadequately controlled COPD and an eosinophilic phenotype. Neither treats acute bronchospasm. Confirm label eligibility, background therapy, exacerbations, eosinophil history, injection training, hypersensitivity, comorbidity, access, and response before continuing.
Use the COPD-specific biologic dose
For adult COPD, dupilumab is 300 mg subcutaneously every two weeks; its COPD regimen does not specify a loading dose. Mepolizumab is 100 mg subcutaneously every four weeks. Do not transfer dupilumab loading regimens from other indications or mepolizumab’s 300 mg EGPA/HES dose to COPD. Both are add-on maintenance treatments, not replacements for acute rescue care.
Interpret the dupilumab evidence population
BOREAS and NOTUS studied patients with eosinophils at least 300 cells per microliter, FEV1 30 to 70 percent predicted, and at least two moderate or one severe exacerbation in the preceding year despite triple inhaled therapy. Chronic productive cough was required, and at least 95 percent had chronic bronchitis. These trial details define the evidence base; the labeled indication is inadequately controlled adult COPD with an eosinophilic phenotype.
Read mepolizumab eosinophil history carefully
MATINEE required eosinophils at least 300 cells per microliter at screening. The label’s METREX efficacy population included at least 150 at screening or at least 300 in the previous year; evidence was insufficient for lower counts without that history. Both trials involved exacerbations despite triple inhaled therapy and FEV1 20 to 80 percent predicted. Do not impose identical trial thresholds on every biologic or select treatment from one isolated count.
Keep maintenance therapy and safety follow-up in place
Starting a biologic does not justify abruptly stopping inhaled or systemic corticosteroids. Any appropriate reduction needs supervision. Teach injection technique and hypersensitivity response. With dupilumab, report new or worsening eye symptoms and review the instruction to avoid live vaccines. With mepolizumab, consider zoster vaccination when medically appropriate. Continue to track exacerbations, symptoms, tolerability, and whether the treatment remains useful.
Store and reschedule dupilumab correctly
Keep the 300 mg device at 2 to 8 degrees Celsius in its carton. After removal from refrigeration, use within 14 days at no more than 25 degrees Celsius or discard. Do not freeze, shake, or heat. Allow 45 minutes at room temperature with the cap on before injection. For a missed every-two-week dose, give it within seven days and resume the original schedule; if more than seven days have passed, give the dose and start a new schedule from that date.
Keep mepolizumab handling clocks separate
Store prefilled mepolizumab devices at 2 to 8 degrees Celsius in the original carton. An unopened carton may be kept at up to 30 degrees Celsius for seven days; after removal from the carton, use the device within eight hours. Allow 30 minutes at room temperature before injection, without external heating. Do not freeze or shake. Give a missed dose as soon as possible and then resume the usual administration day; if the next dose is already due, administer as planned. These instructions apply to prefilled devices, not vial reconstitution.
Address helminth infection before biologic therapy
Both dupilumab and mepolizumab labels instruct clinicians to treat existing helminth infection before starting therapy. If infection develops during treatment and does not respond to anti-helminth therapy, discontinue the biologic until the infection resolves. This is a specific precaution, not a reason to assume that either agent treats infection. Patients or caregivers need product-specific injection training and clinician confirmation that home administration is appropriate.
Quick check
Checking for saved practice…
Lesson
Initial and Follow-Up Pharmacologic Strategy
Initial treatment uses ABE classification. Follow-up treatment starts from the current regimen and follows the dominant treatable trait: persistent dyspnea or exacerbations.
- Initial ABE therapy
- Dyspnea pathway
- Exacerbation pathway
- ICS and eosinophils
- Advanced add-on treatment
Bronchodilator for A, LABA-LAMA for most B and E
Then audit device, diagnosis, rehabilitation, and comorbidity
Use events, eosinophils, infection risk, and current regimen
Start from A, B, or E only when treatment naive
Group A receives a bronchodilator selected for symptom relief, with a long-acting option preferred except for very occasional breathlessness. Group B generally begins LABA-LAMA. Group E generally begins LABA-LAMA, with initial triple therapy considered when eosinophils are at least 300 cells per microliter. LABA-ICS is not encouraged as the routine COPD combination.
Account for access, evidence limits, asthma, and rescue
If initial LABA-LAMA is inappropriate for Group B, GOLD does not favor LABA over LAMA or vice versa for symptom relief; choose according to response and practical factors. Initial algorithms are evidence-informed recommendations with limited direct trial evidence in newly diagnosed untreated patients. Concomitant asthma requires asthma-directed care including ICS. All patients need prescribed short-acting rescue bronchodilation for immediate symptom relief.
Review, assess, then adjust
Maintain a regimen that provides an appropriate response with acceptable safety. Before changing treatment, check symptoms, events, inhaler technique, adherence, rehabilitation, and comorbidity. Start the follow-up algorithm from the actual current regimen, regardless of the original ABE group. If both dyspnea and exacerbations require optimization, use the exacerbation pathway. Reassess response and adverse effects after any change.
Follow the dominant unresolved trait
For dyspnea on one long-acting bronchodilator, escalate to LABA-LAMA. If dyspnea persists on dual therapy, verify the diagnosis, inhaler, adherence, comorbidity, rehabilitation, and device or molecule choice. Ensifentrine may be considered as add-on maintenance treatment in an appropriate adult. Do not add ICS solely for breathlessness without exacerbation biology.
Use eosinophils as a probability marker
GOLD Figure 3.9 branches from a single long-acting bronchodilator after an exacerbation to LABA-LAMA below 300 eosinophils per microliter and to triple therapy at or above 300. The August 2026 GOLD primary-care perspective repeats this diagram in Figure 3. The main report's accompanying prose instead generally recommends LABA-LAMA after an event on monotherapy. The diagram therefore has corroborating guidance, but the wording difference is not an established erratum; individualize the decision using the full clinical context. After a moderate or severe event on LABA-LAMA, consider triple therapy when eosinophils are at least 100. The expected ICS effect is strongest at higher counts and low below 100, but decisions still include attack history, infection and pneumonia risk, and asthma.
Plan ICS de-escalation deliberately
Do not routinely remove ICS from effective triple therapy. Reconsider it when the original indication was inappropriate, response is absent, or significant adverse effects or severe or recurrent pneumonia occur. Balance benefit and harm and arrange close follow-up. Eosinophils at or above 300 cells per microliter increase the likelihood of exacerbations after withdrawal; removing ICS does not mean stopping the long-acting bronchodilators.
Select add-ons after further exacerbations
For exacerbations continuing on LABA-LAMA with eosinophils below 100 cells per microliter, GOLD allows consideration of azithromycin in patients who are not currently smoking, or roflumilast with FEV1 below 50 percent predicted, chronic bronchitis, and a prior hospitalization for an exacerbation. Similar options apply to continued exacerbations on triple therapy. Review QT interval, hearing, microbiology, resistance, interactions, weight, mood, and liver function according to the chosen medicine. These drugs do not substitute for checking inhaler use and alternative causes of deterioration.
Distinguish biologic guidance from label eligibility
For continued exacerbations despite triple inhaled therapy, GOLD considers dupilumab or mepolizumab when blood eosinophils are at least 300 cells per microliter. Its dupilumab pathway requires chronic bronchitis; the mepolizumab pathway includes patients with or without chronic bronchitis. These guideline and trial selection features are more specific than the broad US label wording of inadequately controlled adult COPD with an eosinophilic phenotype. Check both the current label and applicable evidence before specialist selection, and reassess benefit, adverse effects, and continued eligibility.
Review an existing LABA-ICS regimen in context
For COPD without features of asthma, a patient already well controlled on LABA-ICS may continue that regimen. The recommendation against routinely starting LABA-ICS does not require automatically switching every stable patient. With further exacerbations, GOLD recommends triple therapy when eosinophils are at least 100 cells per microliter, or switching to LABA-LAMA below 100. With major persistent symptoms, choose LABA-LAMA or triple therapy according to the prior response to ICS. Coexisting asthma requires its own ICS-containing treatment plan.
Interpret survival evidence by population and comparator
Do not teach that no COPD medicine can affect mortality. GOLD cites IMPACT and ETHOS mortality analyses supporting selected fixed-dose triple inhalers over LABA-LAMA in symptomatic patients with prior exacerbations. IMPACT reported a hazard ratio of 0.72 (95% CI 0.53 to 0.99) versus umeclidinium-vilanterol. ETHOS reported 0.51 (0.33 to 0.80) for its higher-budesonide triple regimen versus glycopyrrolate-formoterol. Neither analysis demonstrated a significant mortality advantage over its ICS-LABA comparator.
Keep mortality findings within their evidence limits
Mortality was not the primary trial endpoint, and the reports incorporated additional vital-status retrieval. ETHOS did not show a significant mortality reduction with its lower-budesonide triple regimen. Interpretation of prior ICS withdrawal at randomization remains debated. These findings do not establish universal survival benefit or reversal of emphysema. They do not justify ICS for isolated dyspnea. Select treatment using exacerbation history, eosinophils, expected benefit and harms; continue smoking cessation, rehabilitation, and indicated oxygen.
Quick check
Checking for saved practice…
Lesson
Risk Reduction, Rehabilitation, Oxygen, and Advanced Care
COPD care changes exposure, infection risk, physical capacity, nutrition, oxygenation, ventilation, and goals in addition to prescribing inhalers.
- Tobacco treatment
- Vaccination
- Pulmonary rehabilitation
- Long-term oxygen
- Ventilation and interventions
Tobacco treatment, clean air, and current vaccination
Exercise, education, self-management, nutrition, and psychosocial care
Use physiologic criteria, reassessment, and patient-centered goals
Remove the injurious exposure
Ask about cigarettes, vaping, cannabis, biomass, occupational dust and fumes, and household or outdoor pollution. Offer behavioral support plus evidence-based tobacco pharmacotherapy. Document readiness, triggers, prior attempts, withdrawal, contraindications, and follow-up. E-cigarettes should not be presented as an established safe cessation treatment.
Make tobacco treatment practical
For an adult ready to stop smoking, combine counseling with an appropriate cessation medicine after reviewing contraindications and preferences. Options include nicotine replacement, varenicline, or bupropion. A nicotine patch can be combined with gum or lozenges for breakthrough cravings; the long-acting and short-acting roles are complementary. Arrange follow-up to address withdrawal, adherence, adverse effects, and relapse. A prior unsuccessful attempt is a reason to refine support, not to abandon treatment.
Prevent infection and restore capacity
Use current local recommendations for influenza, pneumococcal, COVID-19, RSV, Tdap, and zoster vaccination. Pulmonary rehabilitation combines individualized exercise, disease education, self-management, breathing strategies, and nutritional or psychosocial support. It improves exercise capacity, symptoms, and quality of life and is especially important after hospitalization.
Apply current adult pneumococcal options
As reviewed in September 2026, US CDC recommends pneumococcal vaccination routinely from age 50 and for younger adults aged 19 to 49 with risks such as COPD. For an adult who has never received a pneumococcal vaccine, options are PCV20 or PCV21 alone, or PCV15 followed by PPSV23 after one year. The eight-week minimum can be considered with immunocompromise, a cochlear implant, or a cerebrospinal fluid leak; COPD alone does not justify that shortened interval. Prior doses change the pathway: consult the current history-specific schedule rather than restarting automatically. PCV21 lacks serotype 4, so local epidemiology can affect product choice.
Distinguish RSV eligibility from annual vaccination
Current CDC guidance recommends one RSV vaccine dose for all adults aged 75 or older and adults aged 50 to 74 at increased risk; COPD is a qualifying chronic lung condition. RSV vaccination is not currently annual. Do not repeat it solely because another season has arrived if a dose was already received. Eligible unvaccinated adults can receive it any time, preferably before the season in late summer or early fall. Check current guidance, the prior-dose record, and product contraindications before administration.
Tailor rehabilitation and measure useful outcomes
Assess goals, exercise capacity, symptoms, health status, muscle function, and practical barriers such as transport. Adjust training to capability and comorbidity rather than excluding patients solely because of older age or diabetes. Track functional exercise performance, symptom burden, and meaningful daily activities. Spirometry helps establish baseline status, but improved walking or daily function can represent benefit even when FEV1 does not change.
Address malnutrition and muscle loss
Assess weight trajectory, food intake, and muscle function rather than relying on one body-weight measurement. Low body mass and especially low fat-free mass are associated with worse COPD outcomes. For a malnourished patient, nutritional supplementation can improve weight, respiratory muscle strength, and health-related quality of life; coordinate individualized nutrition support with rehabilitation. Do not promise the same benefit from routine supplements for every patient or imply that supplementation reverses emphysema. Unintentional weight loss also warrants evaluation for contributing illness and medication adverse effects.
Prescribe oxygen for the right physiology
Long-term oxygen improves survival in severe chronic resting hypoxemia. GOLD specifies PaO2 at or below 55 mmHg or arterial oxygen saturation at or below 88%, confirmed twice over three weeks in stable COPD. It also lists PaO2 between 55 and 60 mmHg, or arterial saturation of 88%, with pulmonary hypertension, peripheral edema suggesting congestive heart failure, or polycythemia with hematocrit above 55%. Apply the full clinical assessment, not breathlessness alone.
Reassess the oxygen prescription
Recheck long-term oxygen after 60 to 90 days using room-air blood gas or saturation measurements and measurements at the prescribed oxygen flow. Confirm both ongoing need and adequacy of treatment. Hypoxemia during an exacerbation can improve with recovery, so a discharge prescription must not become permanent by default. Routine long-term oxygen for stable moderate resting or exercise-induced desaturation has not improved survival or time to first hospitalization.
Interpret oxygen duration evidence accurately
ATS recommends at least 15 hours daily for severe chronic resting hypoxemia. In REDOX, 241 patients starting oxygen for severe resting hypoxemia were randomized to 24 or 15 hours daily. At one year, 24 hours did not lower hospitalization-or-death risk: hazard ratio 0.99, 95% CI 0.72 to 1.36. This comparison does not establish benefit from less than 15 hours or justify stopping indicated oxygen. Individualize the prescription and review adherence.
Arrange earlier review after an exacerbation
The ATS guideline describes reassessment at one to four weeks and again at 12 to 16 weeks when oxygen begins after a COPD exacerbation. Check resting and exertional oxygenation and revise the prescription as recovery permits. This complements the stable-patient reassessment interval.
Separate ambulatory oxygen from resting indications
ATS conditionally suggests ambulatory oxygen for severe exertional room-air hypoxemia, defined as SpO2 at or below 88% with exertion. Assess benefit, mobility, equipment burden, and preferences. Do not equate this conditional indication with the survival evidence for severe chronic resting hypoxemia.
Make home oxygen usable and safe
Teach patients and caregivers equipment operation, maintenance, troubleshooting, and prescribed use. Address smoking cessation, prohibit smoking around oxygen, avoid flames and sparks, and arrange tubing to reduce falls. Verify that the patient can use the selected system in daily life.
Evaluate stable hypercapnia for nocturnal NIV
ATS conditionally suggests nocturnal noninvasive ventilation in addition to usual care for chronic stable hypercapnic COPD. Its framework uses resting PaCO2 above 45 mmHg outside an exacerbation, with obstructive spirometry. Screen for obstructive sleep apnea before initiation because overlap disease can change the treatment plan. NIV selection and settings require specialist assessment, adherence and interface review, and follow-up of carbon dioxide and symptoms; ATS suggests targeting PaCO2 normalization rather than assuming any pressure setting is equally effective.
Reassess after acute hypercapnic failure
Acute NIV for acidotic respiratory failure and long-term home NIV are separate decisions. ATS suggests reassessing for long-term NIV two to four weeks after resolution rather than routinely initiating it during the acute admission, because hypercapnia may resolve. This does not apply to a patient who remains hypercapnic and cannot be weaned from hospital NIV; continuing support and transitioning to home treatment may be necessary. Do not withdraw needed acute ventilation merely to wait for the reassessment interval.
Refer for phenotype-specific procedures
Persistent disabling symptoms despite optimized treatment and rehabilitation can justify multidisciplinary evaluation for emphysema procedures. CT distribution, hyperinflation, pulmonary function, comorbidities, and patient goals determine suitability. Bullectomy targets a giant bulla compressing usable lung; it is not interchangeable with removal of diffusely emphysematous tissue. Lung transplantation is a separate specialist option for selected patients with very advanced disease, after assessment of contraindications and expected benefit.
Understand lung-volume reduction benefits and risks
In NETT, surgical lung-volume reduction improved survival in the subgroup with upper-lobe-predominant emphysema and low exercise capacity after rehabilitation. Patients with FEV1 at or below 20% predicted plus either homogeneous emphysema or DLCO at or below 20% predicted had higher mortality with surgery than medical care. These findings inform specialist selection, not a universal surgical indication. Endobronchial one-way valves require appropriate target anatomy and little or no interlobar collateral ventilation. Pneumothorax is an important early complication; patients need procedural monitoring and an experienced team.
Integrate palliative care before the terminal phase
Palliative care addresses distressing symptoms, function, emotional and spiritual concerns, caregiver needs, and treatment decisions alongside disease-directed COPD care. It does not require stopping inhalers or waiting until death is imminent. Persistent breathlessness should prompt reassessment of treatable contributors and access to rehabilitation, breathing strategies, and multidisciplinary symptom support. Discuss preferences for resuscitation, ventilation, surrogate decision-making, and future care while the patient can participate; revisit them as illness and goals change.
Distinguish hospice from broader palliative care
Hospice is an end-of-life care model, not a synonym for all palliative care. For US Medicare hospice eligibility, clinicians certify a life expectancy of six months or less, and the patient elects comfort-focused hospice care for the terminal illness and related conditions. Symptom-relieving COPD treatment can remain part of the hospice plan; do not imply that all disease-directed treatment is automatically stopped or that all treatments continue unchanged. Coordinate medicines and services with the hospice team. Survival beyond six months does not automatically end eligibility if the patient remains terminally ill and is recertified. COPD prognosis is uncertain, so advance care planning should begin before a precise survival estimate is possible.
Quick check
Checking for saved practice…
Lesson
Acute Exacerbations, Respiratory Failure, and Recovery
A COPD exacerbation worsens dyspnea and or cough and sputum over days, but pneumonia, pulmonary embolism, heart failure, pneumothorax, arrhythmia, and other emergencies can present similarly.
- Definition and mimics
- Acute bronchodilation
- Steroids and antibiotics
- Oxygen and ventilation
- Discharge prevention
Infection, pollution, pneumonia, embolism, heart failure, or pneumothorax
SABA with or without SAMA; controlled oxygen; steroids, antibiotics, and NIV when indicated
Maintenance therapy, technique, rehabilitation, action plan, and follow-up
Diagnose the event and its competitors
An exacerbation develops over up to about 14 days with worsening dyspnea and or cough and sputum, often with tachypnea or tachycardia. Assess oxygenation, ventilation, mental status, work of breathing, hemodynamics, imaging, ECG, infection, and thrombotic risk. Pneumonia, pulmonary embolism, acute heart failure, pneumothorax, acute coronary disease, and arrhythmia can mimic or worsen the event.
Reverse airflow limitation promptly
Use repeated SABA with or without a short-acting muscarinic antagonist for moderate or severe exacerbations and restart or initiate long-acting maintenance bronchodilation early. Avoid methylxanthines because toxicity outweighs benefit. Delivery can use a metered-dose inhaler with spacer or nebulizer according to severity and ability.
Separate nebulizer driving gas from oxygen treatment
When nebulizing a bronchodilator during an acute COPD exacerbation, GOLD prefers air-driven delivery over oxygen-driven delivery because oxygen-driven nebulization can raise PaCO2. This does not mean withholding oxygen from a hypoxemic patient: provide separately titrated oxygen as needed, assess the blood gases and clinical response, and avoid uncontrolled oxygen exposure. A nebulizer does not itself provide ventilatory support.
Use a short systemic steroid course
For a significant exacerbation requiring systemic corticosteroid, GOLD recommends prednisone-equivalent 40 mg daily for five days. Oral prednisolone is as effective as intravenous administration when oral treatment is feasible. Avoid prolonging exposure routinely; even short courses carry risks.
Apply explicit antibiotic criteria
GOLD 2026 supports antibiotics when increased sputum purulence accompanies at least one of increased dyspnea, fever, or increased sputum volume; when a previous exacerbation had a positive sputum culture; or when invasive or noninvasive mechanical ventilation is required. Dyspnea alone is not an automatic antibiotic indication. Procalcitonin-based protocols are not recommended to decide antibiotic use in COPD exacerbations.
Choose duration and cultures by setting
GOLD recommends five to seven days of antibiotics overall and no more than five days for outpatient exacerbations. Usual empiric antibiotic classes include an aminopenicillin with clavulanate, a macrolide, or a tetracycline; GOLD reserves a quinolone option for selected patients. Select therapy using local resistance, prior organisms, allergies, renal function, and interactions. Obtain sputum or other lower-respiratory cultures with frequent exacerbations, severe obstruction, or mechanical ventilation because resistant organisms, including Pseudomonas, may require different coverage.
Recognize acute respiratory acidosis
ERS/ATS recommends bilevel NIV for acute or acute-on-chronic respiratory acidosis from COPD exacerbation. Consider pH at or below 7.35, PaCO2 above 45 mmHg, and respiratory rate above 20 to 24 breaths/min despite standard therapy. A patient with pH 7.29, PaCO2 62 mmHg and ongoing tachypnea warrants urgent NIV assessment. Elevated carbon dioxide without acidosis alone does not establish this indication.
Monitor response rather than simply applying a mask
Reassess respiratory effort, respiratory rate, blood gases, tolerance, and clinical status promptly after starting NIV. Successful responders usually show improvement in pH or respiratory rate within one to four hours. Lower pH raises failure risk; it is not an automatic prohibition against a closely monitored trial, but rapid access to intubation is essential. Do not delay escalation in a deteriorating patient.
Identify reasons to escalate invasive support
Persistent life-threatening hypoxemia despite support, respiratory or cardiac arrest, inability to tolerate noninvasive support, major aspiration or persistent vomiting, inability to clear secretions, refractory hemodynamic instability, and serious arrhythmias can require invasive ventilation. Impaired consciousness also demands urgent airway assessment. Integrate reversibility and documented treatment preferences without denying intensive care solely because COPD is severe.
Support gas exchange and prevent recurrence
Titrate oxygen, commonly to 88 to 92 percent while blood gases clarify carbon dioxide retention. Noninvasive ventilation is preferred for eligible acute hypercapnic respiratory failure because it reduces intubation and mortality. Before discharge, reconcile inhalers, consider triple therapy when attacks and eosinophils support it, confirm technique and access, arrange rehabilitation and early follow-up, update vaccinations and action planning, and reassess oxygen need after recovery.
Schedule recovery reviews before discharge
Arrange follow-up within one month after hospitalization when possible, with an additional review at about three months. Reassess symptoms, functional recovery, inhaler access and technique, adherence, adverse effects, comorbidities, and lung function when clinically appropriate. Offer pulmonary rehabilitation early after discharge; GOLD describes benefit when started within four weeks. Oxygen started during an exacerbation needs its own earlier reassessment plan because requirements may resolve. Give a clear action plan for renewed deterioration rather than asking the patient to wait for a scheduled visit.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 126 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- GOLD authors: 2026 primary-care recommendations, accepted manuscript, Figure 3
- GOLD 2026: palliative care and emphysema procedures, pages 82-89
- Medicare: hospice eligibility and covered care
- ERS/ATS acute noninvasive ventilation guideline: COPD recommendations
- GOLD 2026 revision 1.3: ventilation indications, Figures 4.8-4.9
- GOLD 2026 full report, revision 1.3: exacerbation pharmacotherapy, pages 103-105
- ATS home oxygen guideline (2020)
- REDOX randomized trial: 24 versus 15 hours of oxygen (2024)
- GOLD 2026 full report: oxygen therapy, pages 76-77
- GOLD 2026 full report: spirometry and diagnostic interpretation, pages 28-31
- Ipratropium 0.02% nebulizer solution prescribing information
- Ipratropium-albuterol nebulizer solution prescribing information
- Atrovent HFA prescribing information and instructions
- Combivent Respimat prescribing information and instructions
- Roflumilast oral prescribing information: dosing, contraindications, and interactions
- GOLD 2026 Pocket Guide: ABE assessment, Figure 2.13
- Trelegy Ellipta prescribing information
- Breztri Aerosphere FDA prescribing information (April 2026)
- Serevent Diskus prescribing information
- Symbicort conventional prescribing information
- Symbicort Aerosphere FDA prescribing information (2026)
- Advair Diskus prescribing information
- Wixela Inhub prescribing information
- Breo Ellipta prescribing information
- Bevespi Aerosphere prescribing information and device instructions
- Duaklir Pressair prescribing information and device instructions
- Anoro Ellipta prescribing information
- Stiolto Respimat prescribing information and device instructions
- Spiriva HandiHaler prescribing information and capsule instructions
- Spiriva Respimat prescribing information
- FDA Lonhala Magnair marketing status
- Lonhala Magnair historical FDA prescribing information (2019)
- Yupelri prescribing information: revefenacin dosing, device and precautions
- Incruse Ellipta prescribing information and device instructions
- Tudorza Pressair prescribing information and device instructions
- Brovana prescribing information: arformoterol dosing and storage
- Striverdi Respimat prescribing information and device instructions
- Perforomist prescribing information: COPD indication, dosing and storage
- GOLD 2026 Report and Pocket Guide
- GOLD 2026 Key Changes Summary
- IMPACT Mortality Analysis (2020)
- ETHOS Mortality Analysis (2021)
- ETHOS Interpretation: Prior ICS Withdrawal (2025)
- ATS: Long-Term NIV in Stable Hypercapnic COPD (2020)
- CDC: Pneumococcal Vaccine Recommendations
- CDC: Risk-Based Pneumococcal Recommendations
- CDC: RSV Vaccine Guidance for Adults
- CDC: How to Quit Smoking
- BTS Guideline: Long-Term Macrolides (2020)
- Ohtuvayre Prescribing Information (April 2026)
- FDA Dupixent Prescribing Information
- FDA Nucala Prescribing Information
- FDA Current Product Labeling
- Alpha-1 Foundation Adult AAT Deficiency Clinical Practice Guideline
- DailyMed Current Medication Labeling